NAD+ formats
Injection and nasal spray
Advertised starting price
From $93/month for each route
Membership
No membership fee advertised
Delivery
Free shipping advertised
Access
Online assessment; prescription subject to clinician approval

The offer in practical terms

CoreAge Rx gives readers two separate NAD+ choices: an injectable preparation and a nasal spray. Both are listed from $93 per month. That creates a straightforward opening comparison, but identical price labels do not make the products interchangeable. Each route needs its own prescription, formulation details and discussion of the evidence relevant to that route. We review the two products separately so the lower-friction format is not mistaken for an equivalent treatment.

The published process begins with an online health questionnaire and clinician review. A shipment follows only if a prescription is appropriate. An application is therefore a request for medical assessment, not a guaranteed purchase.

What the starting price leaves open

The NAD+ pages advertise free delivery, no membership fees and no long-term contracts. Those statements are useful when sorting recurring overhead from the medication price. They do not, by themselves, establish the quantity covered by the lowest price, the exact payment due today, or the date on which another order is processed.

Ask for the prescribed product's concentration, container size, expected refill interval and next charge in one written summary. If the resulting plan differs from the advertised minimum, use that individualized amount in the annual-cost worksheet. Twelve times a starting price is a scenario, not a verified annual quotation.

Injection and nasal comparisons

An injection review should establish the dispensing pharmacy, included supplies and the instructions that accompany the actual vial. A nasal review should establish the bottle volume and pump specifications. A generic photograph cannot settle either question. Nor should a reader transfer storage instructions or treatment expectations from the injection page to the nasal product.

For someone deciding between the two, the first question is which route, if either, a clinician considers appropriate. The financial comparison comes after that decision. Paying less for a format that has not been assessed for the intended use does not establish better value.

How we read the benefit claims

CoreAge Rx markets NAD+ around energy, focus and healthy aging. We treat these as provider claims rather than results demonstrated by our review. NAD+ participates in normal cellular processes, but that fact alone cannot establish that a particular compounded prescription improves fatigue or extends healthy lifespan. The distinction matters when benefit language sounds more precise than the supporting human evidence.

Compounded preparations are not FDA-approved. Our review evaluates published terms and the questions a patient can take to a consultation; it does not certify the pharmacy's current manufacturing practices or substitute for an assessment of persistent symptoms.

Who should examine the details most closely

CoreAge Rx is a useful comparison entry for readers seeking an online route with no separately advertised membership charge. Before paying, confirm what happens if treatment is declined, stopped, or changed after a refill has entered processing. Also ask whom to contact about a shipment problem versus a clinical concern; those issues may require different teams.

Keep the original quote alongside the first pharmacy label and receipt. Matching those documents makes it easier to understand a later price or formulation change. Our featured placement is commercial; it does not establish the lowest total cost or a superior clinical outcome.

Useful distinctions

  • Injection and nasal listings can be reviewed separately
  • No membership fee and free delivery advertised
  • Public starting price for both formats

Limitations to weigh

  • Lowest-price quantity and individual refill terms need confirmation
  • Marketing claims are not independent proof of benefit
  • Commercially featured placement is not a clinical ranking

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. CoreAge Rx NAD+ Injectable Provider
  2. CoreAge Rx NAD+ Nasal Provider
  3. FDA: Compounding questions and answers Regulator
  4. Grant et al. 2019: Human plasma and urine metabolome during NAD+ IV infusion Clinical research